

PATENT

Attorney Docket No.: 3495.0008-08

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc ALIZON et al.)
Serial No.: 08/384,248) Group Art Unit: 1813
Filed: February 6, 1995) Examiner: J. PARKIN RECEIVED (
For: METHOD OF PRODUCING ANTIBODIES TO ANTIGENS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV 1)	Box After Final GEOLIP 1800
Assistant Commissioner for Patents Washington, D.C. 20231	

Sir:

RESPONSE AFTER FINAL TO PAPER NO. 36

In response to the Final Office Action mailed September 17, 1997 (Paper No. 36), applicants submit the following remarks.

REMARKS

Claims 23, 32, and 33 are rejected under 35 U.S.C. § 103(a) as being allegedly unpatentable over Wain-Hobson et al. (1985) in view of Hurn et al. (1980). The Office argues that the availability of the complete nucleotide sequence of the λ-J19 clone enables the production of viral antigens. The Office further argues that, since the sequence of the clone was not disclosed until January of 1985, no priority date prior to this date can be maintained. Consequently, the Office assigns a priority date of February 28, 1985, as the priority date of the instant application, and considers the Wain-Hobson et al. reference as prior art.

LAW OFFICES

FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L. L. P. 1300 I STREET, N. W. WASHINGTON, DC 20005